Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer

BackgroundCombined immunotherapy and antiangiogenic therapy have exhibited synergistic antitumor effects in several cancers. The prognosis of recurrent or metastatic cervical cancer (r/mCC) is poor, especially for patients with prior multi-line treatments. This study aimed to evaluate the efficacy a...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Zhou, Shushu Liu, Ying Zuo, Danial F. Naseem, Yinguang Li, Yin Wang, Cuicui Meng, Yipeng Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Oncology
Subjects:
cervical cancer
immunotherapy
anti-angiogenesis therapy
PD-1
CTLA-4
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1614434/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1614434/full

Similar Items